Glial cell line-derived neurotrophic factor: Characterization of mammalian posttranslational modifications

References

• Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:1130–2.
   PubMed Web of Science ®Google Scholar
• Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 2002;3:383–94.
   PubMed Web of Science ®Google Scholar
• Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M, . The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci. 2005;96:143–8.
   PubMed Web of Science ®Google Scholar
• Runeberg-Roos P, Saarma M. Neurotrophic factor receptor RET: structure, cell biology, and inherited diseases. Ann Med. 2007;39:572–80.
   PubMed Web of Science ®Google Scholar
• Vastag B. Biotechnology: Crossing the barrier. Nature. 2010;466: 916–8.
   PubMed Web of Science ®Google Scholar
• Bartolini A, Di Cesare Mannelli L, Ghelardini C. Analgesic and antineuropathic drugs acting through central cholinergic mechanisms. Recent Pat CNS Drug Discov. 2011;6:119–40.
   PubMedGoogle Scholar
• Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and disease. Annu Rev Neurosci. 2010;33:409–40.
   PubMed Web of Science ®Google Scholar
• Sari Y. Huntington's disease: from mutant Huntingtin protein to neurotrophic factor therapy. Int J Biomed Sci. 2011;7:89–100.
   PubMedGoogle Scholar
• Kokai LE, Bourbeau D, Weber D, McAtee J, Marra KG. Sustained growth factor delivery promotes axonal regeneration in long gap peripheral nerve repair. Tissue Eng Part A. 2011;17:1263–75.
   PubMed Web of Science ®Google Scholar
• Ghitza UE, Zhai H, Wu P, Airavaara M, Shaham Y, Lu L. Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci Biobehav Rev. 2010;35:157–71.
   PubMed Web of Science ®Google Scholar
• Uchida S, Hara K, Kobayashi A, Otsuki K, Yamagata H, Hobara T, . Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron. 2011;69:359–72.
   PubMed Web of Science ®Google Scholar
• Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R, Bunnage M, . Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9:589–95.
   PubMed Web of Science ®Google Scholar
• Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, . Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60:69–73.
   PubMed Web of Science ®Google Scholar
• Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med. 2005;11:703–4.
   PubMed Web of Science ®Google Scholar
• Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg. 2005;102:216–22.
   PubMed Web of Science ®Google Scholar
• Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, . Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59:459–66.
   PubMed Web of Science ®Google Scholar
• Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, . Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010;9:1164–72.
   PubMed Web of Science ®Google Scholar
• Lonka-Nevalaita L, Lume M, Leppänen S, Jokitalo E, Peränen J, Saarma M. Characterization of the intracellular localization, processing, and secretion of two glial cell line-derived neurotrophic factor splice isoforms. J Neurosci. 2010;30:11403–13.
   PubMed Web of Science ®Google Scholar
• Matsudaira P. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem. 1987; 262:10035–8.
   PubMed Web of Science ®Google Scholar
• Parkash V, Leppänen VM, Virtanen H, Jurvansuu JM, Bespalov MM, Sidorova YA, . The structure of the glial cell line-derived neurotrophic factor-coreceptor complex: insights into RET signaling and heparin binding. J Biol Chem. 2008;283:35164–72.
   PubMed Web of Science ®Google Scholar
• Eigenbrot C, Gerber N. X-ray structure of glial cell-derived neurotrophic factor at 1.9 A resolution and implications for receptor binding. Nat Struct Biol. 1997;4:435–8.
   PubMedGoogle Scholar
• Ansorena E, Garbayo E, Lanciego JL, Aymerich MS, Blanco-Prieto MJ. Production of highly pure human glycosylated GDNF in a mammalian cell line. Int J Pharm. 2010;385:6–11.
   PubMedGoogle Scholar
• Silvian L, Jin P, Carmillo P, Boriack-Sjodin PA, Pelletier C, Rushe M, . Artemin crystal structure reveals insights into heparan sulfate binding. Biochemistry. 2006;45:6801–12.
   PubMed Web of Science ®Google Scholar
• Baloh RH, Tansey MG, Johnson EM Jr, Milbrandt J. Functional mapping of receptor specificity domains of glial cell line-derived neurotrophic factor (GDNF) family ligands and production of GFRalpha1 RET-specific agonists. J Biol Chem. 2000;275:3412–20.
   PubMed Web of Science ®Google Scholar
• Horger BA, Nishimura MC, Armanini MP, Wang LC, Poulsen KT, Rosenblad C, . Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci. 1998;18:4929–37.
   PubMed Web of Science ®Google Scholar
• Hoane MR, Puri KD, Xu L, Stabila PF, Zhao H, Gulwadi AG, . Mammalian-cell-produced neurturin (NTN) is more potent than purified Escherichia coli-produced NTN. Exp Neurol. 2000;162:189–93.
   PubMed Web of Science ®Google Scholar
• Fjord-Larsen L, Johansen JL, Kusk P, Tornøe J, Grønborg M, Rosenblad C, . Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol. 2005;195:49–60.
   PubMed Web of Science ®Google Scholar
• Herzog CD, Dass B, Holden JE, Stansell J 3rd, Gasmi M, Tuszynski MH, . Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord. 2007;22:1124–32.
   PubMed Web of Science ®Google Scholar
• Suter-Crazzolara C, Unsicker K. GDNF is expressed in two forms in many tissues outside the CNS. Neuroreport. 1994;5:2486–8.
   PubMed Web of Science ®Google Scholar
• Fletcher AM, Kowalczyk TH, Padegimas L, Cooper MJ, Yurek DM. Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor. Neuroscience. 2011;194:220–6.
   PubMed Web of Science ®Google Scholar
• Immonen T, Alakuijala A, Hytönen M, Sainio K, Poteryaev D, Saarma M, . A proGDNF-related peptide BEP increases synaptic excitation in rat hippocampus. Exp Neurol. 2008;210:793–6.
   PubMed Web of Science ®Google Scholar
• Bradley LH, Fuqua J, Richardson A, Turchan-Cholewo J, Ai Y, Kelps KA, . Dopamine neuron stimulating actions of a GDNF propeptide. PLoS One. 2010;5:e9752.
   PubMed Web of Science ®Google Scholar
• Xu RY, Pong K, Yu Y, Chang D, Liu S, Lile JD, . Characterization of two distinct monoclonal antibodies specific for glial cell line- derived neurotrophic factor. J Neurochem. 1998;70:1383–93.
   PubMed Web of Science ®Google Scholar
• Alfano I, Vora P, Mummery RS, Mulloy B, Rider CC. The major determinant of the heparin binding of glial cell-line-derived neurotrophic factor is near the N-terminus and is dispensable for receptor binding. Biochem J. 2007;404:131–40.
   PubMed Web of Science ®Google Scholar
• Haniu M, Hui J, Young Y, Le J, Katta V, Lee R, . Glial cell line- derived neurotrophic factor: selective reduction of the intermolecular disulfide linkage and characterization of its disulfide structure. Biochemistry. 1996;35:16799–805.
   PubMed Web of Science ®Google Scholar
• Hui JO, Woo G, Chow DT, Katta V, Osslund T, Haniu M. The intermolecular disulfide bridge of human glial cell line-derived neurotrophic factor: its selective reduction and biological activity of the modified protein. J Protein Chem. 1999;18:585–93.
   PubMedGoogle Scholar
• Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, . Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett. 1994;182:107–11.
   PubMed Web of Science ®Google Scholar
• Aoi M, Date I, Tomita S, Ohmoto T. The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages. Neurosci Res. 2000;36:319–25.
   PubMed Web of Science ®Google Scholar
• Piltonen M, Bespalov MM, Ervasti D, Matilainen T, Sidorova YA, Rauvala H, . Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp Neurol. 2009;219:499–506.
   PubMed Web of Science ®Google Scholar
• Lu X, Hagg T. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats. J Comp Neurol. 1997;388:484–94.
   PubMed Web of Science ®Google Scholar
• Kirik D, Georgievska B, Rosenblad C, Björklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur J Neurosci. 2001;13:1589–99.
   PubMed Web of Science ®Google Scholar
• Hadaczek P, Johnston L, Forsayeth J, Bankiewicz KS. Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain. Neuropharmacology. 2010;58:1114–21.
   PubMed Web of Science ®Google Scholar
• Choi-Lundberg DL, Lin Q, Chang YN, Chiang YL, Hay CM, Mohajeri H, . Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science. 1997;275:838–41.
   PubMed Web of Science ®Google Scholar
• Li Q, Ping P, Jiang H, Liu K. Nerve conduit filled with GDNF gene-modified Schwann cells enhances regeneration of the peripheral nerve. Microsurgery. 2006;26:116–21.
   PubMed Web of Science ®Google Scholar
• Kishima H, Poyot T, Bloch J, Dauguet J, Condé F, Dollé F, . Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. Neurobiol Dis. 2004;16:428–39.
   PubMed Web of Science ®Google Scholar
• Sajadi A, Bensadoun JC, Schneider BL, Lo Bianco C, Aebischer P. Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol Dis. 2006;22:119–29.
   PubMed Web of Science ®Google Scholar
• Grandoso L, Ponce S, Manuel I, Arrúe A, Ruiz-Ortega JA, Ulibarri I, . Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats. Int J Pharm. 2007;343:69–78.
   PubMed Web of Science ®Google Scholar